NeurAxis, Inc. (NRXS)
NYSEAMERICAN: NRXS · Real-Time Price · USD
6.20
-0.33 (-5.05%)
Jul 29, 2026, 10:09 AM EDT - Market open
NeurAxis Revenue
NeurAxis had revenue of $1.61M in the quarter ending March 31, 2026, with 79.52% growth. This brings the company's revenue in the last twelve months to $4.28M, up 45.88% year-over-year. In the year 2025, NeurAxis had annual revenue of $3.57M with 32.89% growth.
Revenue (ttm)
$4.28M
Revenue Growth
+45.88%
P/S Ratio
18.89
Revenue / Employee
$178,396
Employees
24
Market Cap
76.78M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.57M | 883.36K | 32.89% |
| Dec 31, 2024 | 2.69M | 225.88K | 9.18% |
| Dec 31, 2023 | 2.46M | -224.69K | -8.37% |
| Dec 31, 2022 | 2.68M | -36.55K | -1.34% |
| Dec 31, 2021 | 2.72M | 791.06K | 40.98% |
| Dec 31, 2020 | 1.93M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Heron Therapeutics | 150.71M |
| Champions Oncology | 59.43M |
| Alterity Therapeutics | 4.43M |
| Rallybio | 858.00K |
| Inovio Pharmaceuticals | 65.34K |
NRXS News
- 1 day ago - NeurAxis to Host Second Quarter 2026 Results and Business Update Call on Tuesday, August 11, 2026 - GlobeNewsWire
- 5 days ago - Neuraxis files to sell 1.92M shares of common stock for holders - TheFly
- 6 days ago - NeurAxis Registration statement: Registration filing - Filings
- 2 months ago - NeurAxis Transcript: Lytham Partners Spring 2026 Investor Conference - Transcripts
- 2 months ago - NeurAxis Slides: Investor presentation - Filings
- 2 months ago - NeurAxis Earnings Call Transcript: Q1 2026 - Transcripts
- 2 months ago - NeurAxis Quarterly report: Q1 2026 - Filings
- 2 months ago - NeurAxis Earnings release: Q1 2026 - Filings